Caribou Biosciences, Inc. (CRBU)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 2.7M | 2.2M | 3.9M | 2.4M |
| Operating Income | -35.4M | -29.4M | -28.5M | -26.3M |
| Net Income | -54.1M | -27.5M | -26.5M | -25.1M |
| Diluted EPS | $-0.58 | $-0.30 | $-0.28 | $-0.26 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 13.9M | 34.5M | 10.0M | 11.2M |
| Operating Income | -106.4M | -116.1M | -166.6M | -136.2M |
| Net Income | -99.4M | -102.1M | -149.1M | -148.1M |
| Diluted EPS | $-1.64 | $-1.38 | $-1.65 | $-1.59 |